Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults With Uncontrolled Asthma

NCT01238861 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

964

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

BIOLOGICAL: Benralizumab 2 mg
BIOLOGICAL: Benralizumab 20 mg
BIOLOGICAL: Benralizumab 100 mg
OTHER: Placebo

Sponsor

MedImmune LLC

Collaborators

[object Object]